"Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study

Andrea Nicolini, Angelo Carpi, Claudio Michelassi, Claudio Spinelli, Massimo Conte, Paolo Miccoli, M. Fini, R. Giardino

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives. - Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means. We hypothesised that carcinoembryonic antigen (CEA), tissue polipeptyde antigen (TPA), breast cancer associated antigen 115 D8/DF3 (CA15.3) tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients. Methods. - From October 1981 to May 1999, 68 (62%) of 109 patients with distant metastases were recruited. Thirty-six (53%) received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15.3 tumour marker panel and negative instrumental examinations ("tumour marker guided" treatment) and 32 (47%) were treated only after radiological confirmation of metastases (conventional treatment). The prognostic factors of the two groups did not show any statistically significant difference. Results. - The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases (lead time) was significantly prolonged in the 36 patients with "tumour marker guided" treatment (17.3±13.1 vs. 2.9±2.9 months, P

Original languageEnglish
Pages (from-to)452-459
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume57
Issue number10
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Salvage Therapy
Tumor Biomarkers
Breast Neoplasms
Survival
Carcinoembryonic Antigen
Neoplasm Metastasis
Antigens
Therapeutics

Keywords

  • Breast cancer
  • Metastasis
  • Treatment
  • Tumour markers

ASJC Scopus subject areas

  • Pharmacology

Cite this

"Tumour marker guided" salvage treatment prolongs survival of breast cancer patients : Final report of a 7-year study. / Nicolini, Andrea; Carpi, Angelo; Michelassi, Claudio; Spinelli, Claudio; Conte, Massimo; Miccoli, Paolo; Fini, M.; Giardino, R.

In: Biomedicine and Pharmacotherapy, Vol. 57, No. 10, 12.2003, p. 452-459.

Research output: Contribution to journalArticle

Nicolini, Andrea ; Carpi, Angelo ; Michelassi, Claudio ; Spinelli, Claudio ; Conte, Massimo ; Miccoli, Paolo ; Fini, M. ; Giardino, R. / "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients : Final report of a 7-year study. In: Biomedicine and Pharmacotherapy. 2003 ; Vol. 57, No. 10. pp. 452-459.
@article{ae559134d43d4be5a4eb395dc5920765,
title = "{"}Tumour marker guided{"} salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study",
abstract = "Objectives. - Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means. We hypothesised that carcinoembryonic antigen (CEA), tissue polipeptyde antigen (TPA), breast cancer associated antigen 115 D8/DF3 (CA15.3) tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients. Methods. - From October 1981 to May 1999, 68 (62{\%}) of 109 patients with distant metastases were recruited. Thirty-six (53{\%}) received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15.3 tumour marker panel and negative instrumental examinations ({"}tumour marker guided{"} treatment) and 32 (47{\%}) were treated only after radiological confirmation of metastases (conventional treatment). The prognostic factors of the two groups did not show any statistically significant difference. Results. - The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases (lead time) was significantly prolonged in the 36 patients with {"}tumour marker guided{"} treatment (17.3±13.1 vs. 2.9±2.9 months, P",
keywords = "Breast cancer, Metastasis, Treatment, Tumour markers",
author = "Andrea Nicolini and Angelo Carpi and Claudio Michelassi and Claudio Spinelli and Massimo Conte and Paolo Miccoli and M. Fini and R. Giardino",
year = "2003",
month = "12",
doi = "10.1016/j.biopha.2003.09.004",
language = "English",
volume = "57",
pages = "452--459",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "10",

}

TY - JOUR

T1 - "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients

T2 - Final report of a 7-year study

AU - Nicolini, Andrea

AU - Carpi, Angelo

AU - Michelassi, Claudio

AU - Spinelli, Claudio

AU - Conte, Massimo

AU - Miccoli, Paolo

AU - Fini, M.

AU - Giardino, R.

PY - 2003/12

Y1 - 2003/12

N2 - Objectives. - Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means. We hypothesised that carcinoembryonic antigen (CEA), tissue polipeptyde antigen (TPA), breast cancer associated antigen 115 D8/DF3 (CA15.3) tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients. Methods. - From October 1981 to May 1999, 68 (62%) of 109 patients with distant metastases were recruited. Thirty-six (53%) received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15.3 tumour marker panel and negative instrumental examinations ("tumour marker guided" treatment) and 32 (47%) were treated only after radiological confirmation of metastases (conventional treatment). The prognostic factors of the two groups did not show any statistically significant difference. Results. - The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases (lead time) was significantly prolonged in the 36 patients with "tumour marker guided" treatment (17.3±13.1 vs. 2.9±2.9 months, P

AB - Objectives. - Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means. We hypothesised that carcinoembryonic antigen (CEA), tissue polipeptyde antigen (TPA), breast cancer associated antigen 115 D8/DF3 (CA15.3) tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients. Methods. - From October 1981 to May 1999, 68 (62%) of 109 patients with distant metastases were recruited. Thirty-six (53%) received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15.3 tumour marker panel and negative instrumental examinations ("tumour marker guided" treatment) and 32 (47%) were treated only after radiological confirmation of metastases (conventional treatment). The prognostic factors of the two groups did not show any statistically significant difference. Results. - The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases (lead time) was significantly prolonged in the 36 patients with "tumour marker guided" treatment (17.3±13.1 vs. 2.9±2.9 months, P

KW - Breast cancer

KW - Metastasis

KW - Treatment

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=0345306243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345306243&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2003.09.004

DO - 10.1016/j.biopha.2003.09.004

M3 - Article

C2 - 14637388

AN - SCOPUS:0345306243

VL - 57

SP - 452

EP - 459

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 10

ER -